01 POLIO Brooks 508
Document text
CenCenCen Centt tterer erers fs f s fs for Disease Coor Disease Coor Disease Coor Disease Co nn nntrtrtr trol ol ol ol andandandand PrPr PrPree eevv vvenen enentiti tition ononon NaNaNaNational Cen tional Centional Centional Cent ttter f er fer fer for or or or ImIm ImImmunizmuniz munizmuniz aa aation antion an tion antion an d Rd Rd Rd Respiespi espiespir rrra aaattttoror orory y y y DiseDiseDiseDise ases asesasesases Photographs and images included in this presentation are licensed solely for CDC/NCIRD online and presentation use. No rights are implied or extended for use in printing or any use by other CDC CIOs or any external audiences.ACIP Polio Vaccination Work Group Oliver Brooks, MD, FAAP ACIP Meeting June 21, 2023 1)Whether more specific guidance on adult vaccination , including use of adult booster doses, can be provided in the context of circulating poliovirus. 2)Whether adults who are immunocompromised should be recommended an additional adult booster of a polio -containing vaccine. 3)Whether fractional doses of IPV ( fIPV ), as prequalified by WHO, should m eet polio vaccination requirements, including for people immigrating to the United States . 4)Consider criteria under which novel Oral Polio Vaccine type 2 (nOPV2) might be used in areas with outbreaks or persistent circulation of poliovirus.Polio Vaccination Work Group Terms of Reference Policy topics under consideration: